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Background/aim: Neuroendocrine disorders are considered a possible pathogenetic mechanism in chronic fatigue syndrome (CFS).
The aim of our study was to determine the function of the hypothalamic–pituitary–adrenal axis (HPA) and thyroid function in women
of reproductive age suffering from CFS.
Materials and methods: The study included 40 women suffering from CFS and 40 healthy women (15–45 years old). Serum levels of
cortisol (0800 and 1800 hours), ACTH, total T4, total T3, and TSH were measured in all subjects. The Fibro Fatigue Scale was used for
determination of fatigue level.
Results: Cortisol serum levels were normal in both groups. The distinctively positive moderate correlation of morning and afternoon
cortisol levels that was observed in healthy women was absent in the CFS group. This may indicate a disturbed physiological rhythm of
cortisol secretion. Although basal serum T4, T3, and TSH levels were normal in all subjects, concentrations of T3 were significantly
lower in the CFS group.
Conclusion: One-time hormone measurement is not sufficient to detect hormonal imbalance in women suffering from CFS. Absence
of a correlation between afternoon and morning cortisol level could be a more representative factor for detecting HPA axis disturbance.
Key words: Chronic fatigue syndrome, hypothalamic–pituitary–adrenal axis, cortisol, thyroid hormones

1. Introduction
According to the most recent definition given by the
Center for Disease Control (CDC) in 2003, chronic
fatigue syndrome (CFS) is a condition of relatively
rapidly developed, medically unexplainable, persistent, or
relapsing fatigue that lasts for at least 6 months, does not
occur after physical exertion, remains after the rest period,
and always results in final reduction of life activities—work,
social, and personal (1,2). The introduction of a single
definition of CFS had the purpose to create clearly defined
diagnostic criteria and to standardize the methodological
approaches in future research. The CDC has established
clear criteria for the diagnosis of CSF (3,4).
Despite numerous studies and large interest among
the scientific community, the etiology of this illness is
still unknown and most studies indicate multifactorial
etiology (5,6). It is assumed that the underlying
pathophysiological mechanism of a complex interaction
between neuroendocrine, humoral, immunological, and
* Correspondence: dajana.lendak@mf.uns.ac.rs

disorders of the autonomic nervous system, with a certain
psychological predisposition leads to the emergence and
persistence of CFS. There is also evidence of oxidative
stress (OS) occurrence, but it is not known whether it is a
cause or a consequence of this syndrome (7,8).
Most of the research efforts in the last 20 years
have been dealing with the research functions of the
hypothalamic–pituitary–adrenal axis (HPA axis). The
original idea that the CFS is associated with dysfunction of
the HPA axis resulted from the similarity of its symptoms
with those of glucocorticoid deficiency, as well as from
research showing that the chronically fatigued person
shows reduced adrenocortical activity (9,10). The available
written sources show no data on a single uniform HPA
axis disturbance in the CFS. There are different disorders
at different levels of the HPA axis disturbances. Activation
of the HPA axis during infection or stress leads to
activation and release of corticotropin—corticotropinreleasing hormone (CRH)—in the central nervous system
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(CNS) and the peripheral tissues. The CRH system is the
main component that responds to stress and the HPA axis
acts as the effector organ. This release contributes to the
induction of behavioral responses, autonomic reactivity,
and hormonal responses via the HPA axis (11).
It is assumed that the organism switches from
hypoactivity to hyperactivity of the stress system, leading to
typical symptoms of fatigue, pain, and low mood through
changes over self-regulatory feedback, after a period of
chronic stress (11). Several mechanisms could lead to
a response of decreased adreno-corticotropic hormone
(ACTH) to stressors, and thus to CFS: hypersecretion
of CRH without the resulting consequential regulation
of target receptors, increased sensitivity to negative
glucocorticoid feedback, reduced availability of free
cortisol, and decreased sensitivity of target tissues to cortisol
(12,13). Mediators of inflammation such as interleukin-1
(IL-1) trigger CRH neurons in the hypothalamus in terms
of negative feedback, resulting in immunosuppressive
effects of glucocorticoids. If hypothalamic neurons do
not respond adequately to cytokine stimulation, there
will be no suppression, which will result in hyperimmune
state (14). Some tests that link the activity of cells of the
immune system with the status of the HPA axis, thyroid,
and sex hormones, point to the mechanism of chronic
inflammation and confirm the possible loss of thyroid
function in CFS, which is exacerbated by the inaction of
the HPA axis (15).
The objectives of our research were to determine the
function of the HPA axis and thyroid function in women
with CFS.
2. Materials and methods
The research was conducted as a cross-sectional study at the
Infectious Diseases Clinic, Clinical Center of Vojvodina in
Novi Sad. The study included 40 women of generative age
(15–45 years) who met the CDC criteria for the diagnosis
of CFS. The youngest subjects were 24 (control group)
and 25 (CFS group) years old. The mean duration of
CFS was 2.29 ± 2.1 years (mean ± SD), with a minimum
of 6 months and a maximum of 10 years. Criteria for
noninclusion in the study were as follows: current acute
or chronic illness (documentation of acute or chronic
infective disease, autoimmune disease, malignancies,
endocrine, neurological disease, cardiovascular and other
chronic disease), psychotic disorders, bipolar affective
disorders (depressive phase), dementia, anorexia, bulimia,
drug and alcohol abuse, and extreme obesity (BMI ≥
40 kg/m2). The control group consisted of 40 healthy
female volunteers (age and BMI matched). The health
condition of the control group subjects was assessed by
detailed anamnestic, laboratory, and clinical examination
that included analysis of urine, total blood count with
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differential leukocyte count, sedimentation, concentration
of urea, creatinine, electrolytes, bilirubin, aspartate
aminotransferase (AST), alanine aminotransferase
(ALT), gamma-glutamyl transpeptidase (GGT), alkaline
phosphatase (ALP), lactate dehydrogenase (LDH), results
of lipid status test, complement components C3 and
C4, antinuclear antibodies (ANA), antimitochondrial
antibodies (AMA), basal serum levels total T4, total T3,
thyroid-stimulating hormone (TSH), basal serum cortisol
levels at 0800 and 1800 hours, and basal plasma ACTH
levels at 0800. Serological investigations included ELISA
tests for IgM and IgG antibodies against adenoviruses,
EBV, Coxsackie B, Parvo B19, Lyme borreliosis, HBs Ag,
anti HCV, and anti HIV.
The study was approved by the Ethics Committee of
the Clinical Center as well as the Ethics Committee of the
Faculty of Medicine in Novi Sad. All the patients in both
groups signed an informed consent for participating in
the examination. In the diagnosis of CFS the diagnostic
algorithm recommended by the CDC was used. As part
of the endocrine tests we analyzed the following values:
basal plasma ACTH and serum cortisol levels at 0800
and 1800, and basal serum levels total T4, total T3, and
thyroid-stimulating hormone (TSH). T3, T4, and TSH
were determined on Abbott Architect i 2000SR (CMIA
methodology). ACTH concentration was determined
Elecsys 2010, Roche Diagnostics machine (ECLIA
methodology). Basal serum cortisol level was determined
by CLIA immunometric methodology on an Advia
Centaur XP machine. Quantification of fatigue, i.e. the
objectification of fatigue and other symptoms related to
CFS, was conducted using the Fibro Fatigue Scale (FFS).
The scale is not intended to diagnose CFS. It represents a
proven instrument that assesses the severity of symptoms
as well as changes in symptoms that occur over time and
is suitable for use in clinical testing (16,17). The FFS is
a visual six-degree self-assessment scale containing 12
questions that the patient gives answers to with the help
of examiners (16,17). A total sum on the FFS (summative
score) represents a degree of expressed fatigue as well as
the degree of all the tested difficulties within CFS.
The results were introduced and presented using
standard statistical variables: mean ± standard deviation
(SD), or median (minimum–maximum), according to the
distribution. The examination of statistical significance of
the parametric data was conducted by ANOVA or Mann–
Whitney test, according to the normality of distribution.
Correlations between investigated parameters were
assessed by Pearson’s correlation test. Significance level
was set at P < 0.05.
3. Results
CFS group patients were 35.43 ± 6.06 (minimum 24,
maximum 45) years old, while control group subjects
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were 35.85 ± 5.89 (minimum 25, maximum 45) years old.
There was no statistically significant difference between
investigated groups in terms of age (P = 0.751). There was
also no significant difference between the investigated
groups in terms of BMI (CFS: mean ± SD = 21.5 ± 1.8 vs.
control group (21.8 ± 2.4), P = 0.758).
Although the mean values of serum cortisol levels at
0800 in the group of patients with CFS were slightly higher
than those of the control group of healthy women, the
difference was not statistically significant (Table 1).
A similar relationship was observed with the levels
of serum cortisol at 1800. Values were higher in CFS
patients than in healthy women, but the difference was not
statistically significant (Table 1).
There was no significant correlation between morning
and afternoon cortisol values in patients with CFS (r
= 0.082, P = 0.072) (Figure 1A). In the group of healthy
women, we found a statistically significant correlation of
moderate degree (r = 0.562, P < 0.001) (Figure 1B).
The basal plasma ACTH levels were slightly higher in
the group of women with CFS than in the control group,
but the difference was not statistically significant (Table 1).
In all subjects, basal serum values of TSH, total T3, and
total T4 were within normal ranges. However, the mean
value of T3 in the CFS group was significantly lower than
in the group of healthy women (Table 1).
Analysis of basal serum values of T4 showed higher
values in the group of patients with CFS than in the group
of healthy women, but the difference was not statistically
significant (Table 1). The mean values of TSH were slightly
lower in patients with CFS than in healthy women, but the
difference was not statistically significant (Mann–Whitney
U value = 729.500, P = 0.497).
The mean values of total FFS scores were significantly
higher in affected subjects (mean = 21.90, SD = 5.23 vs.
mean = 2.93, SD = 1.87, P < 0.0001) than in the control
group of healthy subjects.
We examined whether there was a correlation between
the degree of fatigue, i.e. total score FFS and basal serum

levels of T3, in women in the CFS group, since we found
lower values of T3 in women with CFS. The total FFS
score correlated with the mean basal values of T3 in the
CFS group. There was a statistically significant negative
correlation between low levels of expression (r = –0.355, P
< 0.05) (Table 2; Figure 2).
The analysis of total FFS score value with T4 and TSH
basal serum levels in the affected group did not show a
statistically significant correlation (T4 r = 0.211, P > 0.05,
TSH r = 0.032, P > 0.05) (Table 2).
4. Discussion
Endocrine dysfunction is one of the etiological factors
of CFS. HPA dysfunction and hypocorticism are also
considered possible factors in CFS development.
Sophisticated neuroendocrine mechanisms are most
certainly disturbed in CFS, which is probably triggered
by infection, stress, or oxidative stress. In our study we
found no statistically significant differences in mean
values of morning and afternoon cortisol levels as well as
ACTH among the tested groups. This was also confirmed
by other researchers (18,19). However, Wyller et al. found
significantly lower values of cortisol/creatinine in patients
with CFS (20). This can be explained by methodological
differences in cortisol determination. The literature data
suggest that 20%–25% of patients with CFS and similar
conditions have hypocorticism.
In women with CFS there was no correlation between
the values of afternoon and morning cortisol levels, while
in the group of healthy women there was a strong positive
correlation. The results might be explained by physiological
differences in the rhythm of cortisol secretion. The basal
plasma ACTH levels were within the normal range in
both groups. The first study done on this subject indicated
reduced morning or even evening cortisolemia and
increased basal values of the evening ACTH. Other studies
that investigated this in the past included relatively small
numbers of patients (21,22). On the other hand, several
recent studies, for example the ones done by Altemus et al.,

Table 1. Hormone levels in CFS and control groups.
CFS group

Control group

Mean ± SD or median
(min–max)

Mean ± SD or median
(min–max)

ANOVA F*/Mann–
Whitney U** value

P

Cortisol 0800 (nmol/L)

522.82 ± 153.27

500.49 ± 227.37

0.265*

0.608

Cortisol 1800 (nmol/mL)

247.20± 139.22

216.80± 132.80

0.999*

0.321

ACTH (pg/mL)

22.37± 11.97

20.84± 12.98

0.301*

0.585

T3 (nmol/L)

1.46 ± 0.22

1.64 ± 0.33

8.077*

0.006

T4 (nmol/L)

91.00 ± 12.93

87.66 ± 19.49

0.817*

0.369

TSH (mIU/L)

1.85 (<0.01–13.30)

1.62 (0.60–19.5)

729.50**

0.497
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nmol/L

A

nmol/L

B

cortisol at 1800

cortisol at 0800

cortisol at 0800

Figure 1. Correlations of 8-h and 18-h cortisol levels in the patient group (A) and control group (B).
Table 2. Correlations of FFS with T3, T4, and TSH concentrations
T3
FFS

T4

TSH

Correlation coefficient (r)

–0.355

0.211

0.032

p

<0.05

>0.05

>0.05

Figure 2. Correlations of FFS and total T3 concentrations.

have not found decreased levels of cortisolemia (23). Two
other studies also have not found reduced serum cortisol
levels in CFS patients in comparison to the control group
(12,24).
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There were also a number of studies that dealt with
determining the values of
 free cortisol levels in 24-h urine
and in saliva. In the study performed by Clear et al. in 121
patients and 64 healthy controls the duration of CFS was
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5.4 years and the study included patients with psychiatric
comorbidity. Decreased level of cortisol in the urine in the
CFS group compared to the control group has been verified
and there was no difference detected in cortisol levels
between patients with or without psychiatric comorbidity.
We highlight these results as it is known that depression
often results in high levels of circulating cortisol. Clear et
al. conducted research in a smaller sample of CFS patients,
this time in accordance with the Oxford version of the
CDC and without psychiatric comorbidity and they also
detected lower levels of cortisol in 24-h urine (14).
The available research studies on disorders in the HPA
axis in CFS are somewhat contradictory. Some studies
measuring cortisol levels in urine and saliva confirmed
that levels are lowered while others did not (21,23,24).
Even the precise biological studies that measured free
cortisol levels in 24-h urine or saliva did not yield different
results. There are studies that show a weaker ACTH and
cortisol response in the dynamic tests with human CRH in
CFS, which implies a generally weakened HPA axis in CFS
verified by computed tomography (CT) results for adrenal
glands in CFS (6). The study by Torres-Harding et al.
found a significant relationship between levels of cortisol
in saliva and CFS (fatigue and pain), which also confirms
that cortisol and HPA dysfunction have important roles in
the development of CFS (25).
Although the HPA axis has been extensively tested,
we would like to emphasize that it is still unclear whether
hyporcortisolemia causes fatigue. Recent studies that
investigated polymorphism in glucocorticoid receptor in
CFS suggest that the altered sensitivity to cortisol may be the
cause of the relative hyporcortisolemia. This is supported
by the different degree of fatigue in investigated patients
and this theory rules in favor of genetic predisposition.
On the other hand, immune reaction releases IL-6, which
increases the quantity of free circulating cortisol by
stimulating the hypothalamus CRH neurons and inhibiting
the corticosteroid-building globulin gene (CBG) (26).
All of this links CFS with possible hereditary disorders,
including cortisol transport and CBG gene mutation as
well as glucocorticoid resistance.
In our research, we did not detect decreased morning
and evening values of cortisolemia, but we found “slower”
cortisol response. Once again, we think that it is necessary
to point out that all studies concerning HPA axis disorder
give very contradictory results. Some of them found
flattened cortisol diurnal rhythm (10), but the fact is that
a large number of studies found only weakened HPA axis
function. Torres-Harding et al. measured cortisol in saliva
several times a day in 108 patients with CFS. They found
abnormal daily baseline cortisol pattern using clinical
judgement in 47.2% patients (25). This was present more
in men (62.5%) than in women (40%). Considering the

results of our study and the results of other research, we
suggest that the duration of CFS should be taken into
account, as it eventually leads to exhaustion of the HPA
axis. In our study, mean duration of fatigue was 2.23 years,
and this is not sufficient to cause total exhaustion of the
HPA axis. Moreover, the sample of 40 women is not large
enough to make any definitive conclusions.
In all the examinees, basic serum values of TSH, T3,
and T4 were within physiological limits, but when the
values were compared we noted significantly lower values
of T3 in patients who had CFS.
In the literature available to us, there are no data about
testing of thyroid gland function in CFS, since, as defined,
hyper- or hypothyroidism exclude CFS. Considering this,
our results can be interesting. Fatigue is one of the main
symptoms of hypothyreosis, which, narrowed down to
lower values of T3, suggests that this could be important
from the clinical point of view. What implies the same is
the negative correlation between T3 and FFS. This means
that the patients with lower values of T3 have higher scores
on FFS, i.e. more difficulties typical for CFS. Although T4
makes 90% of the total amount of hormones produced by
the thyroid gland and T3 only 10%, functionally speaking,
both hormones are equally important, because on the
periphery, apart from the rest, T4 converts to T3.
Perhaps the lower values of T3 in people suffering from
CFS could be related to the changes in the level of thyroid
hormones in cases of so-called nonthyroidal illness
syndrome (NTIS). This syndrome is present in chronic
nonthyroid diseases (cardiovascular disease, polycystic
ovary syndrome, chronic renal disease, etc. in which low
T3 and normal T4 levels are observed). This could imply
that CFS is a chronic disease (27,28).
There is a question whether the decrease in T3 level
during any acute or chronic disease (without thyroid
function disorder) represents a pathological result or
an adaptive response to stress, by which the metabolic
activeness is lowered and the loss of energy that is
beneficial for these patients (who are actually euthyroid)
is prevented. The lower level of T3 in people suffering
from CFS might also be referred to as the only possible
adaptive response to stress. Although pituitary–thyroid
dysfunction is considered a neuroendocrine disorder that
is important in the development of CFS, the literature data
are scarce and conflicting. Morkens et al. (29) found high
levels of TSH and normal levels of T4 in patients with CFS,
while results from Wyller at al. (2016) show significantly
higher free T4 concentration in patients with CFS (20).
Our results also show higher T4 levels in patients with
CFS compared to controls, but this difference was not
statistically significant. However, these results may imply
pituitary–thyroid axis dysfunction.
In conclusion, we can only suggest that subtle alteration
of neuroendocrine control mechanisms plays a role in
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the development of CFS, with confirmed dysfunction of
the HPA axis and pituitary thyroid axis. Further research
should investigate the underlying neuroendocrine
mechanisms in the development of CFS. Although it is still

difficult to answer the question whether these hormonal
imbalances are only adaptive mechanisms or pathological
disorders, the fact is they correlate with the level of fatigue,
which is the central clinical symptom of this disorder.
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